1 year ago
India's Pharma Innovation Faces Funding Hurdles, Says DCGI
At a healthcare summit, India's drug controller said that there isn't enough money to fund new medicine ideas in India.
He wants companies to find international investors to help.
The government is also making it easier to follow the rules.
India, known for making generic medicines, needs to start focusing on creating new and valuable medicines, not just copies of existing ones.
Companies like Dr. Reddy's are trying to sell more than just generic medicines.
They are starting new partnerships and buying other businesses to expand their products, like vitamins and medicines to help people quit smoking.
Doctors also emphasized the increasing health issues such as cancer and diabetes.
DCGI stated risk capital for pharma innovation in India is limited.
Corporates should attract international investors.
Regulations shift towards light-touch approach.
Indian pharma needs to expand beyond generics.
Dr. Reddy's Laboratories expanding beyond generics via ventures.
- Who
- Rajeev Singh Raghuvanshi (DCGI), Satish Reddy (Dr Reddy’s Laboratories), and Arvind Lal (Dr Lal PathLabs).
- What
- Discussion on Indian pharma sector at FE Healthcare Summit & Awards 2025.
- Where
- FE Healthcare Summit & Awards
- When
- Wednesday, 2025
- Why
- To address challenges and opportunities in the Indian pharmaceutical sector.
Current State
Future Strategies
Investment
Current State
Risk capital is limited, hindering innovation.
Future Strategies
Needs to be increased to help new products.
Market Strategy
Current State
India focuses on generics.
Future Strategies
Move towards new and valuable medicines.
Key facts
- Event
- FE Healthcare Summit & Awards 2025
- Speaker (DCGI)
- Rajeev Singh Raghuvanshi
- Pharma Focus
- Generics and Innovation
- Company Example
- Dr. Reddy’s Laboratories
- Dr. Reddy's Venture
- Nestlé India
- Health Issue
- Non-communicable diseases

